Minretumomab

Minretumomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetTAG-72
Clinical data
Other namesCC49
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Minretumomab (CC49) is a mouse monoclonal antibody[1] that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.[2][3] Apparently, it never got past Phase I clinical trials for this purpose.[4]

Derivatives

A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric[5] and humanized minretumomab,[6] as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.[7]

Radiopharmaceuticals

Iodine (125I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in radioimmunoassays such as CA 72-4.[8]

Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (131I) and lutetium (177Lu) minretumomab, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in Phase I and II clinical trials.[5]

References

  1. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (3). 1999.
  2. "TAG-72 antigen". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.
  3. Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872. S2CID 205469234.
  4. "Studies found for: CC49". ClinicalTrials.gov.
  5. 1 2 Trahan Rieger P, ed. (2001). Biotherapy (2nd ed.). Jones and Bartlett. pp. 334–335. ISBN 0-7637-1428-3.
  6. Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW (February 2010). "Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72". Cancer. 116 (4 Suppl): 1059–66. doi:10.1002/cncr.24793. PMC 4498458. PMID 20127951.
  7. Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, et al. (2006). "Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)". Bioconjugate Chemistry. 17 (2): 410–8. doi:10.1021/bc0503521. PMID 16536473.
  8. Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, et al. (November 1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer Research. 56 (22): 5293–8. PMID 8912871.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.